Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Core Viewpoint - Beijing JianKai Technology Co., Ltd. anticipates significant growth in its 2025 annual performance, with substantial increases in both revenue and net profit compared to the previous year [2][4]. Performance Forecast - The company expects to achieve an operating revenue of approximately 315 million yuan in 2025, representing an increase of 87.90 million yuan, or 38.71%, compared to the previous year [2][4]. - The projected net profit attributable to the parent company is estimated to be between 60 million and 66 million yuan, an increase of 30.16 million to 36.16 million yuan, or 101.09% to 121.20% year-on-year [2][4]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between 45 million and 50 million yuan, reflecting an increase of 25.52 million to 30.52 million yuan, or 131.01% to 156.68% year-on-year [2][4]. Previous Year Performance - In the previous year, the company reported an operating revenue of 227.10 million yuan [6]. - The total profit was 32.67 million yuan, with a net profit attributable to the parent company of 29.84 million yuan, and a net profit after deducting non-recurring gains and losses of 19.48 million yuan [6]. Reasons for Performance Changes - The anticipated growth in 2025 is primarily attributed to increased order revenue from the sales volume of new drug products launched by overseas clients [8].

Group 1 - ShenNan Electric A expects a net profit increase of 584.66%-721.59% year-on-year for 2025 [1] - Te Yi Pharmaceutical anticipates a net profit increase of 241.55%-339.13% year-on-year for 2025 [1] - RunTu Co. forecasts a net profit increase of 181.05%-227.89% year-on-year for 2025 [1] - QingSong Co. projects a net profit increase of 137.73%-201.74% year-on-year for 2025 [1] - RuiSheng Intelligent expects a net profit increase of 112.00%-139.99% year-on-year for 2025 [1] - JianKai Technology anticipates a net profit increase of 101.09%-121.20% year-on-year for 2025 [1] - XingQi Eye Medicine forecasts a net profit increase of 95.82%-121.56% year-on-year for 2025 [1] - RuiChuang MicroNano expects a net profit increase of approximately 93% year-on-year for 2025 [1] - TianHe Co. projects a net profit increase of 84.35%-169.78% year-on-year for 2025 [1] - ZhongYuan Co. anticipates a net profit increase of 80%-105% year-on-year for 2025 [1] - YiDao Information expects a net profit increase of 76.04%-128.85% year-on-year for 2025 [1] - ShengDa Bio forecasts a net profit increase of 69.93%-120.90% year-on-year for 2025 [1] - HuaRui Precision anticipates a net profit increase of 68.29%-86.99% year-on-year for 2025 [1] - FangZheng Technology expects a net profit increase of 67.06%-98.14% year-on-year for 2025 [1] - JinLing Hotel projects a net profit increase of 65.37%-90.93% year-on-year for 2025 [1] - QiangYi Co. anticipates a net profit increase of 57.87%-71.17% year-on-year for 2025 [1] - LangBo Technology expects a net profit increase of 57.58%-66.53% year-on-year for 2025 [1] - HuaFeng Measurement and Control forecasts a net profit increase of 46%-78% year-on-year for 2025 [1] - Zhaoyi Innovation anticipates a net profit increase of approximately 46% year-on-year for 2025 [1] - JieChang Drive expects a net profit increase of 40%-55% year-on-year for 2025 [1] - ShengYuan Environmental Protection projects a net profit increase of 31.79%-59.24% year-on-year for 2025 [1] - GuangHa Communication anticipates a net profit increase of 21.83%-31.31% year-on-year for 2025 [1] - MaiHe Co. expects a net profit increase of 19.58%-54.76% year-on-year for 2025 [1] Group 2 - YiLing Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan for 2025, turning profitable year-on-year [1] - LiYade anticipates a net profit of 300 million to 380 million yuan for 2025, turning profitable year-on-year [1] - SiRuiPu expects a net profit of 165 million to 184 million yuan for 2025, turning profitable year-on-year [1] - DaMing City anticipates a net profit of 140 million to 165 million yuan for 2025, turning profitable year-on-year [1] - DaHeng Technology expects a net profit of 106 million yuan for 2025, turning profitable year-on-year [1] - GuangHua Technology projects a net profit of 85 million to 120 million yuan for 2025, turning profitable year-on-year [1] - BoTeng Co. expects a net profit of 80 million to 105 million yuan for 2025, turning profitable year-on-year [2] - ZhongBing HongJian anticipates a net profit of 34 million to 46 million yuan for 2025, turning profitable year-on-year [2]

Core Viewpoint - The company, JianKai Technology (688356.SH), forecasts a significant increase in net profit for the year 2025, projecting a net profit attributable to shareholders of the parent company between 60 million to 66 million yuan, representing a year-on-year increase of 30.16 million to 36.16 million yuan, or an increase of 101.09% to 121.20% compared to the previous year [1] Financial Performance - The company expects a year-on-year revenue growth of 38.71% for the year 2025 [1] - The net profit attributable to shareholders of the parent company is projected to increase by 101.09% to 121.20% year-on-year [1] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is expected to increase by 131.01% to 156.68% year-on-year [1] Growth Drivers - The anticipated growth in orders and corresponding profit is primarily driven by the sales ramp-up of products launched by downstream overseas new drug clients [1]

Core Viewpoint - The company expects significant growth in both revenue and net profit for the year 2025, indicating a strong financial outlook and operational performance [1] Financial Performance - The company anticipates achieving an operating revenue of approximately 315 million yuan in 2025, which represents an increase of 87.9 million yuan compared to the previous year, reflecting a year-on-year growth of 38.71% [1] - The projected net profit attributable to the parent company's shareholders is expected to be between 60 million and 66 million yuan, an increase of 30.16 million to 36.16 million yuan compared to the previous year, translating to a year-on-year growth of 101.09% to 121.20% [1]

Core Viewpoint - The company JianKai Technology forecasts a significant increase in net profit for the year 2025, driven by revenue growth from new drug clients in overseas markets [1] Financial Performance - The expected net profit attributable to the parent company for 2025 is projected to be between 60 million to 66 million yuan, representing an increase of 30.16 million to 36.16 million yuan compared to the previous year [1] - This translates to a year-on-year growth of approximately 101.09% to 121.2% [1] - The company's operating revenue is anticipated to grow by 38.71% year-on-year [1] Profitability Metrics - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to increase by 131.01% to 156.68% year-on-year [1] - The growth in profit is primarily attributed to increased order revenue from the sales of new drug products launched by overseas clients [1]

Revenue Projections - The company expects to achieve an annual revenue of approximately CNY 315 million in 2025, an increase of CNY 87.90 million or 38.71% compared to the previous year[4]. - The previous year's revenue was CNY 227.10 million, with a net profit of CNY 29.84 million attributable to the parent company[8]. Profit Projections - The projected net profit attributable to the parent company for 2025 is estimated to be between CNY 60 million and CNY 66 million, representing an increase of CNY 30.16 million to CNY 36.16 million, or a growth of 101.09% to 121.20% year-on-year[5]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between CNY 45 million and CNY 50 million, an increase of CNY 25.52 million to CNY 30.52 million, or a rise of 131.01% to 156.68% year-on-year[5]. Factors Influencing Performance - The significant growth in revenue and profit is primarily attributed to increased order income from the launch of new products by overseas pharmaceutical clients[10]. Audit and Disclosure - The company emphasizes that the performance forecast has not been audited by a registered accountant and is based on preliminary calculations by its financial department[7]. - Investors are advised to note that the forecast data is preliminary and the final audited financial data will be disclosed in the official 2025 annual report[12].

Core Viewpoint - The company, JianKai Technology (688356.SH), expects significant growth in revenue and net profit for the year 2025, driven by increased orders from overseas new drug clients following product launches [1] Financial Projections - The company anticipates achieving an operating revenue of approximately 315 million yuan in 2025, representing a year-on-year increase of 38.71% [1] - The projected net profit attributable to the parent company is expected to be between 60 million and 66 million yuan, indicating a year-on-year increase of 101.09% to 121.20% [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, is forecasted to be between 45 million and 50 million yuan, reflecting a year-on-year increase of 131.01% to 156.68% [1] Growth Drivers - The anticipated growth in revenue and profit is primarily attributed to the increase in order income resulting from the sales ramp-up of products launched by overseas new drug clients [1]

Core Viewpoint - JianKai Technology Co., Ltd. expects to achieve an operating revenue of approximately 315 million yuan in 2025, representing an increase of 87.9032 million yuan, or 38.71%, compared to the previous year [1] Financial Projections - The company anticipates a net profit attributable to the parent company of between 60 million yuan and 66 million yuan for the year 2025, which would be an increase of 30.1622 million yuan to 36.1622 million yuan, reflecting a year-on-year growth of 101.09% to 121.20% [1]

Core Viewpoint - JianKai Technology (688356) expects to achieve a net profit attributable to shareholders of 60 million to 66 million yuan for the fiscal year 2025, representing a year-on-year growth of 101.09% to 121.2% [1] Group 1 - The anticipated profit growth is primarily driven by increased order revenue from the launch of new drug products by overseas clients [1]